AU2003261606A1 - Fused protein with the function of both hemolysis and anticoagulation and the use of it - Google Patents

Fused protein with the function of both hemolysis and anticoagulation and the use of it

Info

Publication number
AU2003261606A1
AU2003261606A1 AU2003261606A AU2003261606A AU2003261606A1 AU 2003261606 A1 AU2003261606 A1 AU 2003261606A1 AU 2003261606 A AU2003261606 A AU 2003261606A AU 2003261606 A AU2003261606 A AU 2003261606A AU 2003261606 A1 AU2003261606 A1 AU 2003261606A1
Authority
AU
Australia
Prior art keywords
protein
anticoagulation
hemolysis
function
linker peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003261606A
Other languages
English (en)
Inventor
Ltd. Beijing Lu Yin Hua Pharmaceutical Sciencetechnology Development Company
Chunna Dong
Bingxing Shi
Zuze Wu
Aiping Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Radiation Medicine of CAMMS
Original Assignee
Institute of Radiation Medicine of CAMMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Radiation Medicine of CAMMS filed Critical Institute of Radiation Medicine of CAMMS
Publication of AU2003261606A1 publication Critical patent/AU2003261606A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2003261606A 2002-09-03 2003-09-03 Fused protein with the function of both hemolysis and anticoagulation and the use of it Abandoned AU2003261606A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNA021290865A CN1480466A (zh) 2002-09-03 2002-09-03 一类溶栓抗凝双功能融合蛋白及应用
CN02129086.5 2002-09-03
PCT/CN2003/000743 WO2004022598A1 (fr) 2002-09-03 2003-09-03 Proteine hybride assurant les fonctions d'hemolyse et d'anticoagulation

Publications (1)

Publication Number Publication Date
AU2003261606A1 true AU2003261606A1 (en) 2004-03-29

Family

ID=31954566

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003261606A Abandoned AU2003261606A1 (en) 2002-09-03 2003-09-03 Fused protein with the function of both hemolysis and anticoagulation and the use of it

Country Status (8)

Country Link
US (1) US8212003B2 (https=)
EP (1) EP1541589B1 (https=)
JP (2) JP2006516113A (https=)
CN (2) CN1480466A (https=)
AT (1) ATE376001T1 (https=)
AU (1) AU2003261606A1 (https=)
DE (1) DE60316967T2 (https=)
WO (1) WO2004022598A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102443065A (zh) * 2005-06-01 2012-05-09 中国人民解放军军事医学科学院放射与辐射医学研究所 特异性抗凝血物质的制备及其应用
CN1896108B (zh) * 2005-06-01 2012-01-04 中国人民解放军军事医学科学院放射与辐射医学研究所 特异性抗凝血物质的制备及其应用
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US8968728B2 (en) * 2006-05-12 2015-03-03 Bharat Biotech International Limited Chimeric fusion proteins
EP2103630B1 (en) * 2006-12-15 2011-11-16 Institute Of Radiation Medicine Academy Of Military Medical Sciences, PLA Preparation of low bleeding anticoagulant fusion protein and its use
CN100519585C (zh) * 2007-02-06 2009-07-29 中国人民解放军军事医学科学院基础医学研究所 P11与sak的融合蛋白及其制备方法和用途
CA2678001C (en) * 2007-02-12 2017-07-11 Stefan Schulte Therapeutic application of kazal-type serine protease inhibitors
EP2915564B1 (en) * 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Antidotes for factor XA inhibitors and methods of using the same
DE102009010611A1 (de) * 2009-02-25 2010-08-26 Siemens Aktiengesellschaft Vorrichtung und Verfahren zur Steuerung einer mit mehreren Brennern ausgestatteten Turbine für flüssige oder gasförmige Brennstoffe
CL2011001887A1 (es) * 2010-08-05 2012-02-03 Council Scient Ind Res Construcciones de proteinas quimericas que poseen propiedades anticoagulantes y tromboliticas; secuencia de acido nucleico que las codifica; vector; celula huesped; metodo de preparacion; formulacion farmaceutica que las comprende; y su uso para inhibir la trombina.
CN102180973B (zh) * 2011-03-18 2012-08-29 重庆大学 靶向多功能防栓融合蛋白及其制备方法和应用
JP2015533483A (ja) * 2012-09-07 2015-11-26 サノフイ メタボリックシンドロームを治療するための融合タンパク質
CN106366200B (zh) * 2015-07-23 2020-04-10 武汉光谷人福生物医药有限公司 制备重组葡激酶-水蛭素融合蛋白的方法
JP7028904B2 (ja) * 2019-03-21 2022-03-02 アカデミア シニカ 合成ペプチド、それを備える薬学的組成物及び血栓塞栓症関連疾患の治療におけるその使用
CN113150168B (zh) * 2021-01-29 2022-11-11 武汉真福医药股份有限公司 一种qk纤溶酶基因-水蛭素融合蛋白的制备方法及应用
KR102789819B1 (ko) * 2021-10-21 2025-03-31 중앙대학교 산학협력단 트롬빈 검출용 신규한 펩타이드 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
GB8927722D0 (en) * 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
US5759542A (en) * 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US6015787A (en) * 1997-11-04 2000-01-18 New England Medical Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain
US6423680B1 (en) * 1998-10-30 2002-07-23 Hsc Research And Development Limited Partnership Inhibitor of platelet activating factor
CN1188522C (zh) * 2001-07-20 2005-02-09 健力福生化技术（上海）有限公司 一种血栓靶向性溶栓蛋白表达质粒及其构建
CN1181099C (zh) * 2002-07-23 2004-12-22 中国人民解放军第二军医大学 兼抗凝溶栓双重功能的血栓靶向融合蛋白mA5UKB

Also Published As

Publication number Publication date
US20060127389A1 (en) 2006-06-15
EP1541589B1 (en) 2007-10-17
EP1541589A4 (en) 2005-11-16
CN1301268C (zh) 2007-02-21
DE60316967T2 (de) 2008-05-08
JP2006516113A (ja) 2006-06-22
WO2004022598A1 (fr) 2004-03-18
DE60316967D1 (de) 2007-11-29
CN1678636A (zh) 2005-10-05
JP2010184930A (ja) 2010-08-26
ATE376001T1 (de) 2007-11-15
EP1541589A1 (en) 2005-06-15
CN1480466A (zh) 2004-03-10
US8212003B2 (en) 2012-07-03

Similar Documents

Publication Publication Date Title
AU2003261606A1 (en) Fused protein with the function of both hemolysis and anticoagulation and the use of it
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
EP2298331A3 (en) Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
MXPA03007563A (es) Recuperacion incrementada de proteinas activas.
EP1624891A4 (en) CLEANING FACTOR FC CHIMERIC PROTEINS FOR THE TREATMENT OF HEMOPHILIA
CY1107248T1 (el) Συντηγμενες πρωτεϊνες
PL377967A1 (pl) Konstrukty fuzyjne i ich zastosowanie do wytwarzania przeciwciał o zwiększonym powinowactwie wiązania receptora Fc i funkcji efektorowej
AU2003228962A1 (en) Ferritin fusion proteins for use in vaccines and other applications
DE60038884D1 (en) Autologes thrombin
WO2003066842A3 (de) Verfahren zur herstellung von rekombinanten proteinen in mikroorganismen
AU2926401A (en) Novel chimeric proteins and methods for using the same
EA200100939A1 (ru) Продолжительно действующие инсулинотропные пептиды
EP1392717A4 (en) FAST CLEAVABLE SUMOFUSION PROTEIN EXPRESSION SYSTEM FOR HEAVY-TO-EXPRESS PROTEINS
DE10075010I1 (de) Fusionsproteine mit immunglobulinanteilen ihre Herstellung und Verwendung
WO2003087768A3 (en) Targets for therapeutic intervention identified in the mitochondrial proteome
ATE342359T1 (de) Design von beta-faltblatt-proteinen mit spezifischen bindungseigenschaften
AU2002252035A1 (en) Modified annexin proteins and methods for preventing thrombosis
GEP20105111B (en) Rage fusion proteins and methods of use
ATE318316T1 (de) In der zellmembran verankertes antikoagulant- fusionsprotein
ATE306498T1 (de) Von zellen präsentierte peptide
ATE200631T1 (de) Verbesserter gewebekleber, zubereitet aus kryopräzipitat
Sheffield et al. Prolonged in vivo anticoagulant activity of a hirudin–albumin fusion protein secreted from Pichia pastoris
ATE368687T1 (de) Thrombopoietinproteine mit verbesserten eigenschaften
WO2008071081A8 (zh) 低出血抗凝血融合蛋白的制备及其应用
WO2003014293A3 (en) Novel polypeptide analogs and fusions and their methods of use

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase